

1 RNA-seq analysis of skeletal muscle in motor neurone disease

2 cases and controls

3 Anna Freydenzon^{1,*}, Shivangi Wani¹, Vanda Bharti¹, Leanne M. Wallace¹,

4 Anjali K. Henders¹, Pamela A. McCombe^{2,3}, Robert D. Henderson^{2,3}, Frederik

5 J. Steyn^{2,4}, Naomi R. Wray^{1,5}, Shyuan T. Ngo^{2,3,5,6,+}, Allan F. McRae^{1,+}

6

7 1 Institute for Molecular Bioscience; The University of Queensland; St Lucia,

8 QLD, 4072; Australia

9 2 Centre for Clinical Research (CCR); The University of Queensland; Herston,

10 QLD, 4029; Australia

11 3 Department of Neurology; Royal Brisbane and Women's Hospital; Brisbane,

12 QLD, 4029; Australia

13 4 The School of Biomedical Sciences; The University of Queensland;

14 Brisbane, QLD, 4072; Australia

15 5 Queensland Brain Institute; The University of Queensland; Brisbane, QLD,

16 4072; Australia

17 6 Australian Institute for Bioengineering and Nanotechnology; The University

18 of Queensland; St Lucia, QLD, 4072; Australia

19

20 + These authors contributed equally

21 * Correspondence: a.freydenzon@uq.edu.au

22 Author emails

23 Anna Freydenzon: a.freydenzon@uq.edu.au

24 Shivangi Wani: s.wani@uq.edu.au

25 Vanda Bharti: v.bharti@uq.edu.au

26 Leanne M. Wallace: l.wallace@uq.edu.au

27 Anjali K. Henders: a.henders@uq.edu.au

28 Pamela A. McCombe: pamela.mccombe@uq.edu.au

29 Robert D. Henderson: Robert.Henderson@health.qld.gov.au

30 Frederik J. Steyn: f.steyn@uq.edu.au

31 Naomi R. Wray: naomi.wray@uq.edu.au

32 Shyuan T. Ngo: s.ngo@uq.edu.au

33 Abstract

34 **Background:** Amyotrophic lateral sclerosis (ALS), the most predominant form of Motor
35 Neuron Disease (MND), is a progressive and fatal neurodegenerative condition that spreads
36 throughout the neuromotor system by afflicting upper and lower motor neurons. Lower motor
37 neurons project from the central nervous system and innervate muscle fibres at motor
38 endplates, which degrade over the course of the disease leading to muscle weakness. The
39 direction of neurodegeneration from or to the point of neuromuscular junctions and the role of
40 muscle itself in pathogenesis has continued to be a topic of debate in ALS research.

41 **Methods:** To assess the variation in gene expression between affected and nonaffected
42 muscle tissue that might lead to this local degeneration of motor units, we generated RNA-
43 seq skeletal muscle transcriptomes from 28 MND cases and 18 healthy controls and
44 conducted differential expression analyses on gene-level counts, as well as an isoform
45 switching analysis on isoform-level counts.

46 **Results:** We identified 52 differentially-expressed genes (Benjamini-Hochberg-adjusted
47 $p < 0.05$) within this comparison, including 38 protein coding, 9 long non-coding RNA, and
48 5 pseudogenes. Of protein-coding genes, 31 were upregulated in cases including with
49 notable genes including the collagenic *COL25A1* ($p = 3.1 \times 10^{-10}$), *SAA1* which is released
50 in response to tissue injury ($p = 3.6 \times 10^{-5}$) as well as others of the SAA family, and the
51 actin-encoding *ACTC1* ($p = 2.3 \times 10^{-5}$). Additionally, we identified 17 genes which
52 exhibited a functional isoform switch with likely functional consequences between cases and
53 controls.

54 **Conclusions:** Our analyses provide evidence of increased tissue generation in MND cases,
55 which likely serve to compensate for the degeneration of motor units and skeletal muscle.

56 **Keywords**

57 Amyotrophic lateral sclerosis, ALS, motor neurone disease, transcriptomics, RNA-seq,
58 differential expression, alternative splicing

59 **Background**

60 Motor neuron disease (MND) is a group of several similar neurodegenerative disorders with
61 highly variable patterns of onset, progression, and symptomology. Amyotrophic lateral
62 sclerosis (ALS), the most predominant motor neuron disease, is identified as featuring both
63 upper and lower motor neuron loss. There is active discussion as to whether MND operates
64 as a ‘dying forward’ phenomenon where initial cell death occurs in the cortical motor
65 neurons and extends down into the corticospinal projections (1), or a ‘dying back’
66 phenomenon where neuromuscular junctions (NMJs) are the first to suffer failure and the
67 pathology proceeds up the axon back into the body of the motor neuron (2). Nevertheless, the
68 progressive loss of upper and lower motor neurons results in the presentation of clinical

69 features including spasticity and brisk reflexes, and muscle weakness and wasting across
70 multiple body regions (3). In MND, muscle weakness and wasting occurs in response to the
71 dismantling of neuromuscular junctions (NMJs) and axonal retraction that ultimately results
72 in the denervation of skeletal muscle and subsequent die-off (4). Compensatory mechanisms
73 can be seen in surviving motor units; axon terminals undergo sprouting to markedly increase
74 reinnervation of skeletal muscle, and this occurs in parallel with abnormally fast firing (5).

75 MND is a highly polygenic disease consisting of over 20 known associated genes, although
76 only ~10% of patients have familial history associated with mutations of large effect (4). One
77 functional mechanism implicated by MND-associated genes is disturbance in RNA
78 metabolism, which has contributed to an increasing research focus exploring transcriptomic
79 machinery (6). One of the most notable genes is *TDP-43*, which undergoes substantial
80 posttranslational modification and aggregation in both MND and frontotemporal dementia
81 (7), leading to targeted RNA instability in its overexpression that results in consequences for
82 ribosome biogenesis and oxidative phosphorylation pathways (8). Similarly, *FUS* is involved
83 in transcriptional regulation through binding to RNA targets to regulate splicing and the
84 removal of minor introns (9). Recent transcriptome-wide studies have been conducted on a
85 variety of different tissues and models to find aberrant differential gene expression reflected
86 in all tested tissue types, including but not limited to the postmortem motor cortex (10),
87 patient whole blood (11), motor neurons from stem-cell derived spinal motor axons (12), and
88 spinal cords from the recently generated *PFN1* mouse model (13). Here, we report a whole
89 transcriptome analysis of skeletal muscle tissue from MND patients, and describe the
90 compensatory mechanisms invoked within MND-afflicted muscle tissue in response to
91 denervation and local cell death.

92 **Methods**

93 **Patient recruitment**

94 Patient recruitment and muscle biopsies were undertaken as described by Steyn et al. 2020
95 (14). Briefly, MND patients who met the revised El-Escorial criteria for ALS (15) at the time
96 of diagnosis were enrolled from the Royal Brisbane and Women's Hospital MND clinic for
97 the collection of skeletal muscle biopsies, along with healthy controls in the form of relatives,
98 friends or community volunteers. For all participants, exclusion criteria were history of a
99 metabolic condition (e.g. Hashimoto's disease) and diabetes mellitus. Participants involved in
100 the study are described in **Table S1**. Muscle biopsies (~200mg) were collected from the
101 vastus lateralis from one leg (the least affected leg for MND participants) using a hollow
102 Bergstrom biopsy needle modified for suction. Samples were placed in Dulbecco's Modified
103 EagleMedium/Ham's F-12 with 0.5% gentamicin for transport to the laboratory. A portion
104 (~50-100mg) of muscle tissue was divided from the primary biopsy, washed three times with
105 room temperature phosphate buffered saline, frozen on dry ice, and stored at -80 degrees
106 Celsius.

107 **RNA sequencing**

108 RNA sequencing was performed on MND and healthy controls for both blood and muscle
109 samples (36 overlapping; 23 cases, 13 controls). RNAseq was performed first on an initial
110 batch with all blood and muscle samples, followed by the same muscle samples being re-run
111 once (split across two additional batches) to increase total sequencing reads.

112 **Muscle**

113 Muscle samples passing QC were contributed by 17 healthy controls and 28 MND cases.

114 Total RNA was extracted from the muscle tissue using a standard Trizol-chloroform
115 extraction method. Post extraction, the total RNA was quantitated using the Epoch microplate
116 spectrophotometer followed by quality assessment on the Agilent Bioanalyzer using the RNA
117 Nano kit. On average the samples yielded 7.4 micrograms of total RNA with an average
118 RNA Integrity Number (RIN) of 8.2.

119 One microgram of DNaseI treated total RNA was then used to prepare libraries for
120 sequencing. The libraries were prepared using Illumina's Truseq stranded total RNA library
121 prep gold kit in conjunction with the TruSeq RNA UD indexes. The libraries were then
122 equimolar pooled and paired end sequencing was carried out on HiSeq 4000 system.

123 **Blood**

124 Blood samples passing QC were contributed to by 13 healthy controls and 24 MND cases.
125 Approximately 2.5mL of whole blood was collected in PAXgene Blood RNA tubes. Total
126 RNA was extracted from these tubes using the PAXgene Blood RNA kit from Qiagen. Post
127 extraction, the total RNA was quantitated using the Nanodrop spectrophotometer followed by
128 quality assessment on the Agilent Bioanalyzer using the RNA Nano kit. On average the
129 samples yielded 4.8 micrograms of total RNA with an average RNA Integrity Number (RIN)
130 of 8.2.

131 500ng of DNaseI treated total RNA was then used to prepare libraries for sequencing. The
132 libraries were prepared using Illumina Truseq stranded total RNA library prep gold kit in
133 conjunction with the TruSeq RNA UD indexes. The libraries were then equimolar pooled and
134 paired end sequencing was carried out on HiSeq 4000 system.

135 **Read processing**

136 Initial QC and read trimming was undertaken using fastp (16), setting a threshold of 1 to pass

137 through all non-empty reads (aberrant reads being filtered in the alignment step). By default,
138 fastp conducts automatic adapter trimming by overlapping read pairs, as well as N-based
139 qualify filtering and polyG tail trimming.

140 Trimming reads were mapped to the GENCODE v32-indexed genome through STAR 2.7.3
141 (17) with non-default parameters suggested by the STAR 2.7.0 manual for ENCODE
142 alignment. These parameters specify that splices are only recognized if they fall over
143 indexed, known splice junctions, sets a maximum number of mismatches to be read length*
144 0.04, limits genomic distance between read mates to 1,000,000 and sets a minimum intron
145 length of 20bp.

146 The STAR-generated genome alignments were then quantified to gene meta-features through
147 Rsubread featurecounts (18), with the parameter requiring both pairs to be mapped. Samples
148 with alignment counts of < 20,000,000 across summed technical replicates were
149 consequently filtered out of the analysis (4 blood, 1 muscle).

150 In addition, Salmon 1.0 (19) was run in quasi-mapping mode to the GENCODE v32
151 transcriptome (indexed over *k*-mer length 17). This was done to verify signals detected in
152 STAR and act as a definitive source of transcripts as compared to the finer STAR genomic
153 alignment method. This was run with the non-default parameters of validateMappings,
154 seqBias, gcBias and useEM. This automatically estimates the library type (paired), runs in
155 selective alignment mode where it ranks potential alignment sites based on mapping score,
156 corrects for hexamer priming and GC biases and uses the expectation maximization (EM)
157 method for abundance estimates.

158 Tximport 1.20 (20) was used to aggregate the Salmon transcript counts across samples to
159 acquire both the summarized gene counts for the analysis complimentary to STAR, as well as

160 the counts of the transcripts for differential isoform analyses.

161 Differential expression analyses

162 STAR-generated read counts were read into DESeq2 1.30.1 (21) to collapse replicates into a
163 single measure, and to estimate size factors and dispersion factors. Genes with ≥ 3 samples
164 with normalized counts ≤ 5 were pruned from the individual blood and muscle sets. The
165 resulting subset of genes were then run through DESeq2's negative binomial GLM with a
166 Wald significance test, increasing maximum iterations to 5,000.

167 The muscle and blood GLMs were fitted with MND as the condition and age and sex as
168 covariates. Additionally, a binary variable indicating whether the samples were replicated
169 across the second or third batch was added to the muscle model. These preliminary models
170 were designated as the 'base' models.

171 The variation in counts was visualized within the muscle and blood samples through a
172 principal component analysis applied to the 500 genes with highest variance across all
173 samples, as well as through plotting the relative log expression on both centered and non-
174 centered counts. Two control muscle samples were consequently dropped from further
175 analysis due to featuring highly irregular counts and variance.

176 The genomic inflation factor (GIF) for each analysis (blood and muscle) was calculated as
177 the median of the χ^2 test statistic divided by the median of the χ^2 distribution with one
178 degree of freedom (22). The GIF is a summary statistic that compares the distribution of test
179 statistics against expectation under the null hypothesis of no association of gene expression
180 with MND and has an expected value of 1 when confounding is absent from the data, under
181 the assumption that at least 50% of tests represent truly null associations. The GIF of the
182 muscle models was found to be high, and as such a surrogate variable analysis (SVA) was

183 conducted individually for blood and muscle using the R `sva` 3.38 package (23). SVA
184 analysis estimates the probability of each gene being an empirical control gene (i.e., not
185 associated with MND) through an iterative re-weighted least squares regression and captures
186 variation outside of a specified model with known covariates. In this case, the SVA was
187 conducted with MND status as the only covariate to preserve in the non-null model. This
188 function also generated a suggested number of SVs to use in differential expression analysis
189 through a permutation procedure.

190 Genes with Benjamini-Hochberg-adjusted p -values falling under the significance threshold of
191 0.05 were deemed as transcriptome-wide significant and were taken forward for further
192 enrichment analyses. The union of genes significant to Salmon and STAR models formed the
193 gene list entered `gprofiler2` 0.2 (24) gene ontology enrichment and the STRING 11.0 (25)
194 protein-protein interaction network tools using default settings. The p -values returned by this
195 enrichment analysis are adjusted for multiple testing by `gprofiler2`'s default `gSCS` algorithm.
196 Additionally, a supplementary analysis was conducted with the Revised Amyotrophic Lateral
197 Sclerosis Functional Rating Scale (ALSFRS-R) (26) lower limb subscore as the outcome,
198 adjusting for age, sex and the estimated surrogate variables. This subscore combined scored
199 answers for questions relating to the ability to walk and the ability to climb stairs, with lower
200 values reflecting decreased ability.

201 Finally, the isoform-level length-scaled transcript counts generated by Salmon for the muscle
202 data were analyzed through the `IsoformSwitchAnalyzeR` (27) 1.12 library in R. This package
203 implements visualization and annotation functions on top of a DEXSeq, which currently
204 implements DESeq2's normalization and estimation approaches to iteratively compare the
205 number of transcripts of a given exon compared to the rest of that gene (28) but in this case
206 for isoforms. Isoforms were annotated to exons through the Gencode v32 primary assembly.

207 Following default prefiltering, isoforms were tested for differential usage using MND status
208 as its condition, adjusted for age, sex and batch effect, then analyzed for alternative splicing
209 as well as predicted the open reading frame (ORF) of each isoform of significantly switched
210 genes. IsoFormSwitchAnalyzer implements multiple functions for the export of all isoform
211 sequences for genes with a significant switch, and the import of the results from external
212 annotation databases utilizing these. The databases were CPAT (using the suggested human
213 coding threshold of 0.364) (29) for coding potential, SignalP (30) for predicting signal
214 peptide sites, IUPred2A (31) to predict intrinsically disordered regions (IDRs) and Pfam (32)
215 to predict protein domains.

216 **Results**

217 Quality control of the RNAseq reads for each sample using PHRED scores indicated the
218 quality was high, with the main batch containing mean scores at each base pair across reads
219 and samples of > 30 . However, the samples demonstrated some form of degradation
220 (potentially from long-term storage), particularly for blood. Mean genome alignment over all
221 blood and muscle samples through STAR was 54.4% and 87.6% respectively, while the
222 proportion of those which were assigned to exons were 29.8% and 58.2% respectively. For
223 Salmon, a mean of 74.1% of reads mapped to the transcriptome and were successfully
224 assigned a feature in muscle, whereas this number was only 40% in blood. The proportions
225 of the reads successfully assigned to a feature are plotted in **Figure S1** for STAR and **Figure**
226 **S2** for Salmon.

227 A principal component analysis of the transcript levels revealed a differing pattern of
228 variation between the blood and muscle analyses (**Figure 1**). The second principal
229 component of both blood and muscle (explaining 7.2% and 8.4% of variance in gene
230 expression, respectively), captured sex differences (correlation $r = 0.90$ with $p = 4.9 \times$

231 10^{-14} for blood, and $r = -0.89$ with $p = 2.6 \times 10^{-16}$ for muscle). The first principal
232 component in muscle (explaining 22.3% of expression variance) captured differences
233 between cases and controls. The second principal component in muscle is significantly
234 correlated with the lower limb subscore of the ALSFRS-R when estimating the PCA in case
235 counts only ($r = 0.46$, $p = 0.014$). The relative log expression of the counts (centered and
236 non-centered) passing QC is displayed within **Figure S3**. Similar observations with regards
237 to the principal components and correlations apply to the counts as generated through STAR
238 (**Figure S4**).

239 Testing for case-control differences in gene-expression levels in muscle while correcting for
240 age, sex and replicate batch effect identified additional confounding within the data. The
241 genomic inflation factor (GIF) of Salmon and STAR were 2.53 and 3.47 respectively, with
242 3258 and 6874 transcriptome-wide significant genes detected under the adjusted p-value of
243 0.05 (**Figure S5**). This was corrected with the addition of an automatically determined
244 number of surrogate variables to each model as calculated by permutation procedure. With
245 this correction the GIF falls to 1.18 and 1.13, with 38 and 26 significant genes for Salmon
246 and STAR-aligned data respectively. For the blood transcriptome analysis, such inflation was
247 not an issue (a GIF of 0.85 and 1.01 in Salmon and STAR respectively, with two significant
248 genes each) and as such no SVs were added to the model.

249 Of the 38 and 26 genes detected by Salmon and STAR respectively, there was an intersection
250 of 12 (**Table 1**) with the same direction of fold change for both methods. The complete list of
251 transcriptome-wide genes for each model in each tissue type as well as their test statistics can
252 be found in individual tabs of **Table S2**. Of the 52 genes identified by either Salmon and
253 STAR models, 9 were long non-coding RNAs and 5 were pseudogenes. Of the 38 protein-
254 coding genes, 7 had lower expression and 31 had higher expression in MND cases versus

255 controls. As one of these genes, *AHRR*, is a known smoking biomarker in blood (33) we
256 conducted an additional iteration of the ‘base’ model for muscle with the addition of ever-
257 smoked status (23 never, 22 ever). MND status was found to be significantly associated with
258 *AHRR* count in the STAR model ($\log_2FC = 1.98$, $p = 0.0085$), whereas smoking history was
259 not ($\log_2FC -0.11$, $p = 0.88$).

260 A gene ontology enrichment analysis conducted on the results of each method (**Table 2**)
261 revealed shared enrichment for the GO biological processes term of acute phase response
262 ($p = 1.4 \times 10^{-3}$ and $p = 5.5 \times 10^{-4}$ for Salmon and STAR respectively), attributable to the
263 components of serum amyloid A within the set. Other notable terms enriched in the
264 significant results for Salmon were cardiac muscle tissue morphogenesis ($p = 4.4 \times 10^{-3}$),
265 positive regulation of synapse assembly ($p = 4.7 \times 10^{-3}$), and tissue migration ($p = 7.3 \times$
266 10^{-3}). For STAR, notable terms were skeletal muscle tissue growth ($p = 9.7 \times 10^{-3}$),
267 axonogenesis involved in innervation ($p = 8.4 \times 10^{-3}$) and neutrophil clearance ($p = 7.0 \times$
268 10^{-3}). However, these terms test as enriched due to having one or two significant genes
269 detected from a small pool of other genes in the global set annotated with the term. The
270 unified set of differentially expressed proteins between STAR and Salmon in muscle was
271 identified to have significantly more interactions (9) than expected (4, $p = 0.01$) according to
272 the STRING pathway analysis, indicating a likely biological relation if not interaction
273 between them (**Figure S6**).

274 Within the blood sample, the *ODZI* homolog pseudogene *AL0087071*, notably found on the
275 X-chromosome, was the only gene differentially expressed by both Salmon and STAR
276 methods (respective \log_2FC s of 3.14 and 3.07, with a $p = 1.9 \times 10^{-6}$ and $p = 3.5 \times 10^{-6}$,
277 **Table S3**). *EDH2* was not detected by the STAR aligner though was significantly expressed
278 in Salmon (\log_2FC of -1.75; $p = 7.0 \times 10^{-7}$) and the expression of *FSDIL* was only found

279 significant in STAR (\log_2FC of 0.57; $p = 2.0 \times 10^{-6}$).

280 The results of the supplementary analyses on the 28 cases in predicting the ALSFRS-R lower
281 limb subscores are reported in **Table S4**. The STAR model identified 11 genes significantly
282 expressed in change of scoring and the Salmon model identified 10, with 3 genes (*IGFNI*,
283 *PBX1*, and *TMEM9*) sharing association in both. Both models were adjusted for with two
284 additional surrogate variables (as the number automatically suggested by the function).

285 A total of 17 genes were identified with isoform switches within the muscle sample falling
286 underneath the FDR-adjusted p-value (q-value) of 0.05 and having predicted functional
287 consequences to the expressed protein. The list of features, their direction of consequence and
288 the genes falling under each is listed in **Table S5**. The individual per-isoform tests for each
289 gene are available in **Table S6**. No significant ($FDR < 0.05$) directionality of functional
290 consequences of these isoform differences was observed for any genomic feature, although
291 there was a slight increase in switching to longer transcripts (8:6 longer vs. shorter switches)
292 and an increase in exon number gain (6:3 gain vs. loss of exon count).

293 From the isoform switches with functional consequences, only *SAA2* was represented within
294 our main gene-level analysis. *SAA2* featured an increase of its ENST00000256733 isoform
295 fraction by 24% ($q = 5.74 \times 10^{-11}$) correlated with a decrease of its ENST00000528349
296 isoform fraction by 25% ($q = 9.84 \times 10^{-11}$). The resulting functional consequence was an
297 overall decrease in transcript length by a shortened 3' UTR and the reduction of intron 3-4
298 from 3090 to 394 bp, increasing its predicted coding potential (**Figure 2**). Two other isoform
299 switches with predicted gain in coding potential are *PLCE1* (**Figure S7**) and *SAMD4A*
300 (**Figure S8**). *PIP5K1B* (**Figure S9**) and *MYH3* (**Figure S10**) also have gain in domains
301 which indicate that the isoform with increased expression encodes the more complete version
302 of the protein.

303 **Discussion**

304 The majority of studies on muscle changes associated with MND have been performed in
305 mice (34,35) or iPSC-derived cell-culture (36). To our knowledge, our study is one of the
306 first investigations into the transcriptomic machinery in human MND muscle tissue and
307 provides a substantial increase in the number of individuals examined. We identify 38
308 protein-coding genes differentially expressed between MND cases and controls with 31 of
309 these being upregulated in cases. Muscle biopsies were sampled from the healthier leg in
310 MND cases.

311 Serum amyloid A transcripts (specifically *SAA1*, *SAA2* and the *SAA2-SAA4* readthrough,
312 contiguously located on chromosome 11) were highly expressed in MND patients. SAA is
313 persistently elevated in other chronic inflammatory diseases and a reliable indicator of
314 inflammation due to an up-to 1000-fold increase in plasma levels during acute phase
315 responses (37). In a heightened response, SAA most often becomes associated with the lipid
316 surface of high-density lipoproteins (HDLs), possibly as a stabilized hub to interact with
317 other cellular components (38). In its association with HDL cholesterol, SAA is indicated to
318 be involved in stimulating the inflammatory response within the innate immune system (39).
319 Other acute phase proteins such as C-reactive protein and CD14 have been detected as
320 elevated in MND sera, and increased levels of these are reported to be associated with disease
321 progression and mortality rate (40). In addition to the aforementioned acute phase proteins,
322 several components of the complement system including C3 (41), C4 (42), and C5a/C5b-9
323 (43) have been reported to be higher in the whole blood, serum or plasma of ALS cases to
324 controls in previous studies. As such, it may be of value in the future to investigate local
325 accumulation of SAA as a biomarker for disease progression and as a representation of the
326 overall inflammatory response.

327 Several genes associated with tissue generation are detected as positively expressed in cases.
328 *FST* (follistatin) is a receptor agonist which binds to other transforming growth factor- β
329 ligands, including myostatin and activin-A which would otherwise limit muscle mass without
330 inhibition (44). Additionally, *FST* has an antagonistic effect on several bone morphogenic
331 proteins, of which it forms a complex with and alters signaling to induce muscle hypertrophy
332 while reducing atrophy (45). *MYH3*, a myosin heavy-chain encoding gene primarily
333 expressed embryonically, was not captured by the gene-based analyses; however, the
334 differential isoform expression analysis indicated a heightened expression of its most
335 complete isoform within MND cases. This is of particular interest as *MYH3* has been
336 indicated as a valid and robust biomarker for skeletal muscle tissue regeneration across all
337 ages in other muscle-wasting diseases such as Duchenne muscular dystrophy (46). Muscle
338 tissue does not exist in the body solely as actin filaments, but bundled within a complex net
339 of connective tissue and infiltrating immune cells (47). Other genes instrumental in tissue
340 development and differentiation found expressed higher in cases are the keratin *KRT80* (48),
341 the actin-binding protein encoding *SHROOM3* which is utilized for epithelial folding in
342 neural tube closure (49), and filamentous actin-binding ectodermal-neural cortex 1 *ENC1*
343 (50).

344 Several transcripts found over-expressed in MND cases are not principally expressed by
345 skeletal muscle tissues in adulthood. For instance, *ACTC1* was found to be significantly
346 upregulated but not *ACTA1*. *ACTC1* encodes the α -cardiac muscle actin which constitutes
347 < 5% of skeletal muscle by adulthood, whereas *ACTA1* encodes the almost-identical
348 predominant muscular isoform α -skeletal muscle actin (51). Within a small case study of 7
349 congenital myopathy patients with a complete lack of α -skeletal muscle actin, α -cardiac actin
350 was shown to constitute muscle tissues and the highest amount correlated to the participant
351 with the best muscular function (52). However, as *ACTA1* has been previously identified to

352 be increased as a function of compensatory hypertrophy in a small real-time PCR study of 5
353 ALS patients, a larger sample size may capture the increased expression of both it and
354 *ACTC1* (53). *ANKRD1/CARP* is the ankryn repeat domain most present in cardiac tissue and
355 is shown to be over-expressed within MND muscle compared to controls unlike its skeletal
356 muscle paralog, *ANKRD2/ARPP*. However, *ANKRD1* expression has also been noted to
357 increase in skeletal muscle with denervation-induced atrophy in murine models (54).

358 The expression of extracellular matrix components and collagens *COL19A1* and *COL25A1*
359 was also found to be increased with muscle tissue genes such as *ACTC1*. *COL25A1*, encoding
360 the collagen type XXV alpha 1 chain, is a known Alzheimer's risk gene (55) for its role in
361 assisting the formation of characteristic senile plaques when over-expressed in the brain (56).
362 The cleavage of *COL25A1* creates the proteolytic CLAC (collagenous Alzheimer amyloid
363 plaque component), and as such has the alias of *CLAC-P* (precursor) (57). Collagen XXV is
364 expressed primarily in skeletal muscle during development, acting as a required factor in
365 myofiber fusion from myoblasts in early myogenesis (58). *COL25A1*-KO mice nearly
366 completely failed to innervate skeletal muscle tissue during development by not being able to
367 elongate and branch motor axon bundles, indicating it as a required component to initial
368 intramuscular motor innervation (59). Collagen XIX structures part of the basement
369 membranes, and is present in a host of different tissues including skeletal muscle, axons,
370 epithelia and brain intraneurons (60). As collagens are vital in the production of functional
371 skeletal muscle tissue, their increased expression in MND further supports the evidence of
372 attempted muscle repair as a compensatory response. Higher *COL19A1* expression levels in
373 MND muscle biopsies have already been linked to faster progression of the disease (61).

374 A few other highly upregulated genes of note include some that are influenced by the
375 multiple upregulated transcription factors in the set (*SPI* and *MYCL*). The increased

376 expression of *TDO2* and *AHR* may indicate the presence of prior *AHR* upregulation, which
377 has been indicated to be invoked in neural cell proliferation (62). Following *AHR* and the
378 aforementioned *SAAI*, tryptophan catabolism enzyme *TDO2* has the largest positive fold-
379 change in expression. *TDO2* is ordinarily expressed in the liver as a tryptophan regulator and
380 is also known as an oncogene commonly expressed in most cancers (63). While the products
381 of the catabolic kynurenine pathway include metabolites used for neurotransmission and
382 immune regulation, *TDO2* depletes free tryptophan used for proliferation of T-cells and
383 produces kynurenine that inhibits the proliferation of effector T lymphocytes and promoting
384 regulatory T-cell differentiation, and activates the transcription factor *AHR* (64). The
385 kynurenine pathway itself produces metabolites that influence energy homeostasis in skeletal
386 muscle and other tissues, and kynurenic acid (a product of the pathway) increases energy
387 utilization while also acting as an *AHR* ligand (65).

388 **Conclusions**

389 In summary, we identify 52 genes whose expression in muscle is significantly associated
390 with MND cases versus controls, with the majority showing increased expression in cases.
391 These genes encode vital structural components of muscle, particularly in regenerative or
392 early developmental processes. This provides novel insight into the repair mechanisms
393 triggered in the presence of neurodegeneration and muscle wasting in MND, as well as the
394 chronic inflammation within these tissues as evidenced by expression of acute-phase
395 proteins.

396 **Abbreviations**

397 *ALS-FRS-R*: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale

398	<i>ALS:</i>	Amyotrophic lateral sclerosis
399	<i>EM:</i>	Expectation maximalization
400	<i>GIF:</i>	Surrogate variable analysis
401	<i>lncRNA:</i>	Long non-coding RNA
402	<i>MND:</i>	Motor neurone disease
403	<i>NMJ:</i>	Neuromuscular junction
404	<i>ORF:</i>	Open reading frame
405	<i>PC:</i>	Protein coding
406	<i>PCA:</i>	Principal component analysis
407	<i>PP:</i>	Processed pseudogene
408	<i>RIN:</i>	RNA integrity number
409	<i>TUP:</i>	Transcribed unprocessed pseudogene.
410	<i>UP:</i>	Unprocessed pseudogene

411 **Declarations**

412 Ethics approval and content to participate

413 All work performed in this study was approved by the Royal Brisbane and Women's Hospital
414 and University of Queensland human research ethics committees. All participants provided
415 written informed consent.

416 Consent for publication

417 Not applicable.

418 Availability of data and materials

419 The data that support the findings of this study are available on request from the
420 corresponding author. The raw transcript data are not publicly available due to ethical
421 restrictions; however, gene and transcript counts have been made available. The datasets
422 generated during and/or analysed during the current study are available in the University of
423 Queensland data collection repository, <https://doi.org/10.48610/b722f1f>.

424 Competing interests

425 The authors declare that they have no competing interests.

426 Funding

427 This research was supported through funding from the Scott Sullivan MND Research
428 Fellowship to S.T.N. (2015-2020; MND and Me Foundation and RBWH Foundation),
429 FightMND Mid-Career Fellowship (to S.T.N.), MNDRA Charcot Grant (GIA 1701 to S.T.N.
430 and F.J.S.), the National Health and Medical Research Council Australia (1101085 to S.T.N.
431 and F.J.S., 1113400 & 1173790 to N.R.W.) and the Australian Research Council (Future
432 Fellowship 200100837 to A.F.M.).

433 Authors' contributions

434 A.F., A.F.M., and N.R.W. wrote the paper. A.F. conducted the analyses. A.F.M., N.R.W.,
435 and S.T.N. conceptualized this work. S.W and V.B. processed the samples for sequencing.
436 L.M.W. and A.K.H. allocated laboratory resources and supervised sample processing. P.A.M.
437 and R.D.H. provided samples. S.T.N. and F.J.S. performed the muscle biopsies. All authors
438 read and approved the final manuscript.

439 Acknowledgements

440 The authors thank all patients and participants who provided biological samples for use in

441 this research.

442 **References**

- 443 1. Cappello V, Francolini M. Neuromuscular Junction Dismantling in Amyotrophic Lateral
444 Sclerosis. *IJMS*. 2017 Oct 3;18(10):2092.
- 445 2. Manzano R, Toivonen JM, Moreno-Martínez L, Torre M, Moreno-García L, López-Royo T,
446 et al. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for
447 therapy. *Br J Pharmacol*. 2021 Mar;178(6):1279–97.
- 448 3. Morris J. Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An
449 Overview. *The Neurodiagnostic Journal*. 2015 Sep;55(3):180–94.
- 450 4. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. *Eur J Neurol*.
451 2020 Oct;27(10):1918–29.
- 452 5. Weddell T, Bashford J, Wickham A, Iniesta R, Chen M, Zhou P, et al. First-recruited motor
453 units adopt a faster phenotype in amyotrophic lateral sclerosis. *The Journal of*
454 *Physiology [Internet]*. 2021 Jul 14 [cited 2021 Jul 20];n/a(n/a). Available from:
455 <https://doi.org/10.1113/JP281310>
- 456 6. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. *Nature*.
457 2016 Nov;539(7628):197–206.
- 458 7. Xue YC, Ng CS, Xiang P, Liu H, Zhang K, Mohamud Y, et al. Dysregulation of RNA-Binding
459 Proteins in Amyotrophic Lateral Sclerosis. *Front Mol Neurosci*. 2020 May 29;13:78.
- 460 8. Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, Li X, et al. Abnormal RNA
461 stability in amyotrophic lateral sclerosis. *Nat Commun*. 2018 Dec;9(1):2845.
- 462 9. Butti Z, Patten SA. RNA Dysregulation in Amyotrophic Lateral Sclerosis. *Front Genet*.
463 2019 Jan 22;9:712.
- 464 10. Dols-Icardo O, Montal V, Sirisi S, López-Pernas G, Cervera-Carles L, Querol-Vilaseca M, et
465 al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral
466 sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2020 Sep;7(5):e829.
- 467 11. van Rheenen W, Diekstra FP, Harschnitz O, Westeneng HJ, van Eijk KR, Saris CGJ, et al.
468 Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study.
469 Raoul C, editor. *PLoS ONE*. 2018 Jun 25;13(6):e0198874.
- 470 12. Nijssen J, Aguila J, Hoogstraaten R, Kee N, Hedlund E. Axon-Seq Decodes the Motor
471 Axon Transcriptome and Its Modulation in Response to ALS. *Stem Cell Reports*. 2018
472 Dec;11(6):1565–78.
- 473 13. Barham C, Fil D, Byrum SD, Rahmatallah Y, Glazko G, Kiaei M. RNA-Seq Analysis of Spinal
474 Cord Tissues from hPFN1G118V Transgenic Mouse Model of ALS at Pre-symptomatic
475 and End-Stages of Disease. *Scientific Reports*. 2018 Sep 13;8(1):13737.

- 476 14. Steyn FJ, Li R, Kirk SE, Tefera TW, Xie TY, Tracey TJ, et al. Altered skeletal muscle glucose-
477 fatty acid flux in amyotrophic lateral sclerosis. *Brain Communications*. 2020 Sep
478 24;fcaa154.
- 479 15. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the
480 diagnosis of amyotrophic lateral sclerosis. *Ann Neurol*. 2000 Jan 1;1(5):293–9.
- 481 16. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
482 *Bioinformatics*. 2018 Sep 1;34(17):i884–90.
- 483 17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
484 universal RNA-seq aligner. *Bioinformatics*. 2013 Jan;29(1):15–21.
- 485 18. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better
486 for alignment and quantification of RNA sequencing reads. *Nucleic Acids Research*. 2019
487 May 7;47(8):e47–e47.
- 488 19. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware
489 quantification of transcript expression. *Nat Methods*. 2017 Apr;14(4):417–9.
- 490 20. Sonesson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level
491 estimates improve gene-level inferences. *F1000Res*. 2015;4:1521.
- 492 21. Anders S, Huber W. Differential expression of RNA-Seq data at the gene level – the
493 DESeq package. *BMC Bioinformatics*. 2010;11:1–24.
- 494 22. Devlin B, Roeder K. Genomic Control for Association Studies. *Biometrics*.
495 1999;55(4):997–1004.
- 496 23. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch
497 effects and other unwanted variation in high-throughput experiments. *Bioinformatics*.
498 2012 Mar 15;28(6):882–3.
- 499 24. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web
500 server for functional enrichment analysis and conversions of gene lists (2019 update).
501 *Nucleic Acids Research*. 2019 Jul 2;47(W1):W191–8.
- 502 25. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:
503 protein–protein association networks with increased coverage, supporting functional
504 discovery in genome-wide experimental datasets. *Nucleic Acids Research*. 2019 Jan
505 8;47(D1):D607–13.
- 506 26. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a
507 revised ALS functional rating scale that incorporates assessments of respiratory
508 function. *Journal of the Neurological Sciences*. 1999 Oct 31;169(1):13–21.
- 509 27. Vitting-Seerup K, Sandelin A. IsoformSwitchAnalyzeR: analysis of changes in genome-
510 wide patterns of alternative splicing and its functional consequences. *Bioinformatics*.
511 2019 Nov 1;35(21):4469–71.


- 512 28. Anders S, Reyes A, Huber W. Detecting differential usage of exons from RNA-seq data.
513 Genome Research. 2012 Oct 1;22(10):2008–17.
- 514 29. Wang L, Park HJ, Dasari S, Wang S, Kocher JP, Li W. CPAT: Coding-Potential Assessment
515 Tool using an alignment-free logistic regression model. Nucleic Acids Research. 2013 Apr
516 1;41(6):e74–e74.
- 517 30. Almagro Armenteros JJ, Tsirigos KD, Sønderby CK, Petersen TN, Winther O, Brunak S, et
518 al. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nature
519 Biotechnology. 2019 Apr 1;37(4):420–3.
- 520 31. Mészáros B, Erdős G, Dosztányi Z. IUPred2A: context-dependent prediction of protein
521 disorder as a function of redox state and protein binding. Nucleic Acids Research. 2018
522 Jul 2;46(W1):W329–37.
- 523 32. Mistry J, Chuguransky S, Williams L, Qureshi M, Salazar GA, Sonnhammer ELL, et al.
524 Pfam: The protein families database in 2021. Nucleic Acids Research. 2021 Jan
525 8;49(D1):D412–9.
- 526 33. Reynolds LM, Wan M, Ding J, Taylor JR, Lohman K, Su D, et al. DNA Methylation of the
527 Aryl Hydrocarbon Receptor Repressor Associations With Cigarette Smoking and
528 Subclinical Atherosclerosis. Circulation: Cardiovascular Genetics. 2015 Oct 1;8(5):707–
529 16.
- 530 34. Ehmsen JT, Kawaguchi R, Mi R, Coppola G, Höke A. Longitudinal RNA-Seq analysis of
531 acute and chronic neurogenic skeletal muscle atrophy. Scientific Data. 2019 Sep
532 24;6(1):179.
- 533 35. Gonzalez de Aguilar JL, Niederhauser-Wiederkehr C, Halter B, De Tapia M, Di Scala F,
534 Demougin P, et al. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis
535 mouse model. Physiological Genomics. 2008 Jan 1;32(2):207–18.
- 536 36. Lynch EM, Robertson S, FitzGibbons C, Reilly M, Switalski C, Eckardt A, et al.
537 Transcriptome analysis using patient iPSC-derived skeletal myocytes: Bet1L as a new
538 molecule possibly linked to neuromuscular junction degeneration in ALS. Experimental
539 Neurology. 2021 Nov 1;345:113815.
- 540 37. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. Journal of
541 Leukocyte Biology. 2015 Dec;98(6):923–9.
- 542 38. Webb NR. High-Density Lipoproteins and Serum Amyloid A (SAA). Curr Atheroscler Rep.
543 2021 Feb;23(2):7.
- 544 39. Sack GH. Serum amyloid A – a review. Mol Med. 2018 Dec;24(1):46.
- 545 40. Beers DR, Zhao W, Neal DW, Thonhoff JR, Thome AD, Faridar A, et al. Elevated acute
546 phase proteins reflect peripheral inflammation and disease severity in patients with
547 amyotrophic lateral sclerosis. Sci Rep. 2020 Dec;10(1):15295.


- 548 41. Chen X, Feng W, Huang R, Guo X, Chen Y, Zheng Z, et al. Evidence for peripheral immune
549 activation in amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*. 2014
550 Dec 15;347(1):90–5.
- 551 42. Kjældgaard AL, Pilely K, Olsen KS, Øberg Lauritsen A, Wørlich Pedersen S, Svenstrup K, et
552 al. Complement Profiles in Patients with Amyotrophic Lateral Sclerosis: A Prospective
553 Observational Cohort Study. *J Inflamm Res*. 2021;14:1043–53.
- 554 43. Mantovani S, Gordon R, Macmaw JK, Pfluger CMM, Henderson RD, Noakes PG, et al.
555 Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient
556 blood. *J Neuroimmunol*. 2014 Nov 15;276(1–2):213–8.
- 557 44. Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, et al. Regulation of
558 muscle mass by follistatin and activins. *Mol Endocrinol*. 2010/09/01 ed. 2010
559 Oct;24(10):1998–2008.
- 560 45. Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C, et al. The bone
561 morphogenetic protein axis is a positive regulator of skeletal muscle mass. *Journal of*
562 *Cell Biology*. 2013 Oct 21;203(2):345–57.
- 563 46. Guiraud S, Edwards B, Squire SE, Moir L, Berg A, Babbs A, et al. Embryonic myosin is a
564 regeneration marker to monitor utrophin-based therapies for DMD. *Human Molecular*
565 *Genetics [Internet]*. 2018 Oct 9 [cited 2022 Feb 24]; Available from:
566 <https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddy353/5124574>
- 567 47. Mukund K, Subramaniam S. Skeletal muscle: A review of molecular structure and
568 function, in health and disease. *WIREs Systems Biology and Medicine*. 2020 Jan
569 1;12(1):e1462.
- 570 48. Li C, Liu X, Liu Y, Liu X, Wang R, Liao J, et al. Keratin 80 promotes migration and invasion
571 of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. *Cell*
572 *Death Dis*. 2018 Oct;9(10):1009.
- 573 49. Haigo SL, Hildebrand JD, Harland RM, Wallingford JB. Shroom Induces Apical
574 Constriction and Is Required for Hingepoint Formation during Neural Tube Closure.
575 *Current Biology*. 2003 Dec;13(24):2125–37.
- 576 50. Cui Y, Yang J, Bai Y, Li Q, Yao Y, Liu C, et al. ENC1 Facilitates Colorectal Carcinoma
577 Tumorigenesis and Metastasis via JAK2/STAT5/AKT Axis-Mediated Epithelial
578 Mesenchymal Transition and Stemness. *Front Cell Dev Biol*. 2021 Mar 16;9:616887.
- 579 51. Sztal TE, McKaige EA, Williams C, Ruparella AA, Bryson-Richardson RJ. Genetic
580 compensation triggered by actin mutation prevents the muscle damage caused by loss
581 of actin protein. *Stainier Dyr, editor. PLoS Genet*. 2018 Feb 8;14(2):e1007212.
- 582 52. Nowak KJ, Sewry CA, Navarro C, Squier W, Reina C, Ricoy JR, et al. Nemaline myopathy
583 caused by absence of α -skeletal muscle actin. *Ann Neurol*. 2007 Feb;61(2):175–84.

- 584 53. Jensen L, Jørgensen LH, Bech RD, Frandsen U, Schrøder HD. Skeletal Muscle Remodelling
585 as a Function of Disease Progression in Amyotrophic Lateral Sclerosis. *Biomed Res Int*.
586 2016;2016:5930621.
- 587 54. Laure L, Suel L, Roudaut C, Bourg N, Ouali A, Bartoli M, et al. Cardiac ankyrin repeat
588 protein is a marker of skeletal muscle pathological remodelling: Cardiac ankyrin repeat
589 protein in muscle plasticity. *FEBS Journal*. 2009 Feb;276(3):669–84.
- 590 55. Forsell C, Björk BF, Lilius L, Axelman K, Fabre SF, Fratiglioni L, et al. Genetic association to
591 the amyloid plaque associated protein gene COL25A1 in Alzheimer’s disease. *Neurobiol*
592 *Aging*. 2010 Mar;31(3):409–15.
- 593 56. Tong Y, Xu Y, Scearce-Levie K, Ptáček LJ, Fu YH. COL25A1 triggers and promotes
594 Alzheimer’s disease-like pathology in vivo. *Neurogenetics*. 2010 Feb;11(1):41–52.
- 595 57. Hashimoto T, Fujii D, Naka Y, Kashiwagi-Hakozaki M, Matsuo Y, Matsuura Y, et al.
596 Collagenous Alzheimer amyloid plaque component impacts on the compaction of
597 amyloid- β plaques. *acta neuropathol commun*. 2020 Dec;8(1):212.
- 598 58. Gonçalves TJM, Boutillon F, Lefebvre S, Goffin V, Iwatsubo T, Wakabayashi T, et al.
599 Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle
600 formation. *Sci Rep*. 2019 Dec;9(1):5878.
- 601 59. Tanaka T, Wakabayashi T, Oizumi H, Nishio S, Sato T, Harada A, et al. CLAC-P/Collagen
602 Type XXV Is Required for the Intramuscular Innervation of Motoneurons during
603 Neuromuscular Development. *Journal of Neuroscience*. 2014 Jan 22;34(4):1370–9.
- 604 60. Calvo AC, Moreno L, Moreno L, Toivonen JM, Manzano R, Molina N, et al. Type XIX
605 collagen: a promising biomarker from the basement membranes. *Neural Regen Res*.
606 2020 Jun;15(6):988–95.
- 607 61. Calvo AC, Cibreiro GA, Merino PT, Roy JF, Galiana A, Rufián AJ, et al. Collagen XIX Alpha 1
608 Improves Prognosis in Amyotrophic Lateral Sclerosis. *Aging and disease*. 2019;10(2):278.
- 609 62. Juricek L, Coumoul X. The Aryl Hydrocarbon Receptor and the Nervous System. *IJMS*.
610 2018 Aug 24;19(9):2504.
- 611 63. Hoffmann D, Dvorakova T, Stroobant V, Bouzin C, Daumerie A, Solvay M, et al.
612 Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma
613 Cells and in Intratumoral Pericytes of Most Cancers. *Cancer Immunol Res*. 2020
614 Jan;8(1):19–31.
- 615 64. Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, et al.
616 The therapeutic potential of targeting tryptophan catabolism in cancer. *Br J Cancer*.
617 2020 Jan 7;122(1):30–44.
- 618 65. Liu JJ, Movassat J, Portha B. Emerging role for kynurenines in metabolic pathologies.
619 *Current Opinion in Clinical Nutrition & Metabolic Care* [Internet]. 2019;22(1). Available
620 from: <https://journals.lww.com/co->

621 clinicalnutrition/Fulltext/2019/01000/Emerging_role_for_kynurenines_in_metabolic.15.
622 aspx
623

624 **Figures**





633

634 **Figure 2.** Visualization of isoform expression in the transcriptome-wide significant gene SAA2. The
 635 coloured plots at the top show three transcripts (detected via Salmon), annotated for their inclusion of
 636 protein domains as well as the site of their transcription start and termination sites. The top transcript
 637 is predicted to have high coding potential through CPAT. The bottom graphs individually delineate
 638 the difference in mean counts between cases and controls in the expression of the gene and its
 639 constituent isoforms. The rightmost graph indicates the isoform expression as a proportion of the total
 640 expression across all isoforms within cases and controls separately, indicating a greater proportion of
 641 expression for the coding variant and a decreased proportion of expression for the second non-coding
 642 variant.

643

644 Tables

645 **Table 1.** Overlap of transcriptome-wide significant differences between MND cases and controls

646 from STAR and Salmon models with log2 fold change and Benjamini-Hochberg adjusted *p*-values.

647 Bolded names are significant in both models. lncRNA: long non-coding RNA; PC: protein coding;

648 PP: processed pseudogene; UP: Unprocessed pseudogene; TUP: transcribed unprocessed pseudogene.

Name	Chr	Start	Length	Type	Description	STAR			Salmon		
						log ₂ FC	log ₂ SE	<i>p</i>	log ₂ FC	log ₂ SE	<i>p</i>
AC004490.1	19	2 212 029	3537	lncRNA	Novel transcript, antisense to dot11	—	—	—	0.80	0.20	5.7×10^{-5}
AC010878.1	2	37 816 915	1047	PP	Serine/threonine kinase receptor associated protein (strap) pseudogene	2.17	0.56	1.0×10^{-4}	2.89	0.63	5.4×10^{-6}
AC013275.1	2	119 476 428	10 919	lncRNA	Setr antisense rna 1	-2.96	0.74	6.0×10^{-5}	-2.98	0.72	4.0×10^{-5}
AC068580.4	11	1 734 821	29 134	PC	Novel protein	0.57	0.30	5.9×10^{-2}	1.79	0.41	1.3×10^{-5}
AC087457.1	15	34 755 084	58 422	lncRNA	Novel transcript, antisense to actc1	1.61	0.36	6.0×10^{-6}	0.42	0.15	5.7×10^{-3}
AC103740.1	15	62 827 675	56 360	lncRNA	Novel transcript, antisense to tln2	0.79	0.13	3.3×10^{-9}	0.03	0.12	8.1×10^{-1}
ACP5	19	11 574 660	4349	PC	Acid phosphatase 5, tartrate resistant	-0.49	0.28	7.4×10^{-2}	-1.54	0.37	3.8×10^{-5}
ACTC1	15	34 790 230	5320	PC	Actin alpha cardiac muscle 1	1.25	0.41	2.1×10^{-3}	2.09	0.49	2.3×10^{-5}
AHRR	5	271 670	166 622	PC	Aryl-hydrocarbon receptor repressor	4.25	0.89	2.0×10^{-6}	2.84	0.64	8.8×10^{-6}
AL161665.2	14	32 200 433	1304	lncRNA	Novel transcript	-0.98	0.22	8.0×10^{-6}	-0.89	0.23	1.2×10^{-1}
AL390755.2	13	110 123 208	2027	TEC	Tec	1.38	0.54	1.1×10^{-2}	3.57	0.87	4.4×10^{-5}
ANKRD1	10	90 912 096	9181	PC	Ankyrin repeat domain 1	2.24	0.47	1.4×10^{-6}	2.61	0.47	2.0×10^{-8}
AP5M1	14	57 268 924	29 819	PC	Adaptor related protein complex 5 subunit mu 1	0.17	0.04	7.3×10^{-6}	0.18	0.14	1.9×10^{-1}
ATP23	12	57 906 039	53 110	PC	Atp23 metalloproteinase and atp synthase assembly factor homolog	-0.30	0.17	6.9×10^{-2}	-1.22	0.28	1.8×10^{-5}
BMS1P4	10	73 715 843	14 627	TUP	Bms1 pseudogene 4	0.42	0.10	2.9×10^{-5}	0.44	0.14	1.3×10^{-3}
CDK4	12	57 747 727	8287	PC	Cyclin dependent kinase 4	0.12	0.06	3.5×10^{-2}	0.64	0.13	6.7×10^{-7}
CDKN2B	9	22 002 903	6403	PC	Cyclin dependent kinase inhibitor 2b	0.84	0.19	1.4×10^{-5}	0.78	0.24	1.4×10^{-3}
CH3L1	1	203 178 931	7774	PC	Chitinase 3 like 1	2.30	0.49	3.0×10^{-6}	1.04	0.34	2.3×10^{-3}
CHRNA1	2	174 747 592	40 344	PC	Cholinergic receptor nicotinic alpha 1 subunit	0.99	0.24	2.8×10^{-5}	1.22	0.28	1.6×10^{-5}
COL19A1	6	69 866 556	345 913	PC	Collagen type xix alpha 1 chain	2.26	0.48	3.1×10^{-6}	1.16	0.37	1.9×10^{-3}
COL25A1	4	108 808 725	494 028	PC	Collagen type xxv alpha 1 chain	1.72	0.41	2.5×10^{-5}	3.18	0.50	3.1×10^{-10}
DCLK1	13	35 768 652	362 655	PC	Doublecortin like kinase 1	1.08	0.19	2.6×10^{-8}	1.45	0.30	1.3×10^{-6}
DLEU2L	1	63 547 082	3555	lncRNA	Deleted in lymphocytic leukemia 2 like	1.09	0.18	4.1×10^{-9}	1.34	0.24	1.3×10^{-8}
EFCAB7	1	63 523 372	49 322	PC	Ef-hand calcium binding domain 7	0.77	0.16	8.7×10^{-7}	0.34	0.33	3.0×10^{-1}
ENC1	5	74 627 406	14 019	PC	Ectodermal-neural cortex 1	0.70	0.21	7.5×10^{-4}	1.14	0.27	2.3×10^{-5}
FST	5	53 480 626	6509	PC	Follistatin	1.39	0.31	7.5×10^{-6}	1.87	0.39	1.2×10^{-6}
KRT80	12	52 168 996	23 019	PC	Keratin 80	1.95	0.53	2.2×10^{-4}	2.76	0.54	3.7×10^{-7}
LCMT1-AS1	16	25 085 168	26 388	lncRNA	Lcmt1 antisense rna 1	0.36	0.14	7.8×10^{-3}	1.27	0.28	4.9×10^{-6}
LINC00211	2	37 820 498	55 777	lncRNA	Long intergenic non-protein coding rna 211	2.14	0.50	1.7×10^{-5}	0.02	0.26	9.4×10^{-1}
LINC00626	1	168 784 012	8875	lncRNA	Long intergenic non-protein coding rna 626	—	—	—	3.62	0.71	3.8×10^{-7}
LRRN3	7	111 091 006	34 449	PC	Leucine rich repeat neuronal 3	0.27	0.16	8.5×10^{-2}	1.43	0.34	2.1×10^{-5}
LRTM1	3	54 918 231	48 858	PC	Leucine rich repeats and transmembrane domains 1	0.50	0.31	1.1×10^{-1}	2.95	0.68	1.2×10^{-5}
MERTK	2	111 898 607	130 955	PC	Mer proto-oncogene, tyrosine kinase	-0.63	0.14	4.1×10^{-6}	-0.80	0.29	5.8×10^{-3}
MTCO3P39	4	49 246 021	518	PP	Mt-co3 pseudogene 39	—	—	—	0.94	0.21	7.1×10^{-6}
MTND3P22	4	49 246 601	315	PP	Mt-nd3 pseudogene 22	—	—	—	1.18	0.28	2.9×10^{-5}
MUC19	12	40 393 395	177 438	PC	Mucin 19, oligomeric	-0.37	0.39	3.5×10^{-1}	3.22	0.77	2.7×10^{-5}
MYCL	1	39 895 426	6831	PC	Mycl proto-oncogene, bhlh transcription factor	1.40	0.36	1.1×10^{-4}	1.90	0.43	9.4×10^{-6}
NGDN	14	23 469 689	40 174	PC	Neuroguidin	-0.05	0.07	4.8×10^{-1}	-0.27	0.07	4.4×10^{-5}
PDESB	5	77 210 449	219 359	PC	Phosphodiesterase 8b	0.23	0.13	8.6×10^{-2}	1.90	0.41	3.8×10^{-6}
PEG10	7	94 656 325	13 371	PC	Paternally expressed 10	0.62	0.22	5.7×10^{-3}	1.48	0.37	5.8×10^{-5}
PNPLA3	22	43 923 792	40 697	PC	Patatin like phospholipase domain containing 3	1.98	0.44	6.4×10^{-6}	1.42	0.35	5.6×10^{-5}
RBM44	2	237 798 389	44 420	PC	Rna binding motif protein 44	0.52	0.12	1.1×10^{-5}	0.07	0.28	7.9×10^{-1}
RIN3	14	92 513 781	175 214	PC	Ras and rab interactor 3	-0.44	0.11	3.7×10^{-5}	-0.85	0.38	2.5×10^{-2}
SAA1	11	18 266 660	3718	PC	Serum amyloid a1	3.05	0.53	9.0×10^{-9}	3.40	0.57	1.9×10^{-9}
SAA2-SAA4	11	18 231 423	17 213	PC	Saa2-saa4 readthrough	—	—	—	4.01	0.75	8.0×10^{-8}
SAA2	11	18 239 223	9421	PC	Serum amyloid a2	2.09	0.44	1.7×10^{-6}	1.24	0.30	3.6×10^{-5}
SHROOM3	4	76 435 229	348 025	PC	Shroom family member 3	0.85	0.33	1.0×10^{-2}	2.72	0.61	6.9×10^{-6}
SLC47A2	17	19 678 288	40 692	PC	Solite carrier family 47 member 2	1.43	0.27	1.1×10^{-7}	3.17	0.51	4.3×10^{-10}
SP1	12	53 380 176	36 271	PC	Sp1 transcription factor	-0.12	0.05	1.9×10^{-2}	-0.26	0.06	2.2×10^{-5}
SYT15	10	46 578 217	15 957	PC	Synaptotagmin 15	-0.13	0.18	4.7×10^{-1}	-1.25	0.28	1.2×10^{-5}
TDO2	4	155 854 738	65 669	PC	Tryptophan 2,3-dioxygenase	2.76	0.63	1.3×10^{-5}	4.23	0.79	8.8×10^{-8}
VN1R83P	19	21 289 554	445	UP	Vomerol nasal 1 receptor 83 pseudogene	0.70	0.17	4.5×10^{-5}	0.67	0.20	7.3×10^{-4}

649

650 **Table 2.** Enriched gene ontology (GO) terms for both Salmon and STAR models, as generated from
 651 TopGO. The total number of annotated genes from the greater set is followed by the number of those
 652 which are significantly differentially expressed, as well as the enrichment of the term as calculated by
 653 Fisher’s exact test. Significant/background genes are subset to those with GO terms (27/14475 for
 654 salmon and 19/13588 for STAR).

GO.ID	Term	Genes			Fisher <i>p</i>
		Annotated	Significant	Expected	
Salmon					
GO:0006953	Acute-phase response	30	2: SAA1, SAA2	0.06	1.4×10^{-3}
GO:0055008	Cardiac muscle tissue morphogenesis	53	2: ANKRD1, ACTC1	0.10	4.4×10^{-3}
GO:0051965	Positive regulation of synapse assembly	55	2: LRMT1, LRRN3	0.10	4.7×10^{-3}
GO:0090130	Tissue migration	271	2: ACTC1, SP1	0.51	7.3×10^{-3}
GO:0045607	Regulation of inner ear auditory receptor cell differentiation	5	1: MYCL	0.01	9.3×10^{-3}
GO:0019441	Tryptophan catabolic process to kynurenic	5	1: TDO2	0.01	9.3×10^{-3}
GO:0036155	Acylglycerol acyl-chain remodeling	5	1: PNPLA3	0.01	9.3×10^{-3}
GO:0070814	Hydrogen sulfide biosynthetic process	5	1: SP1	0.01	9.3×10^{-3}
STAR					
GO:0006953	Acute-phase response	25	2: SAA1, SAA2	0.03	5.5×10^{-4}
GO:1903566	Positive regulation of protein localization to cilium	5	1: EFCAB7	0.01	7.0×10^{-3}
GO:0097350	Neutrophil clearance	5	1: MERTK	0.01	7.0×10^{-3}
GO:0036155	Acylglycerol acyl-chain remodeling	6	1: PNPLA3	0.01	8.4×10^{-3}
GO:0060385	Axonogenesis involved in innervation	6	1: COL25A1	0.01	8.4×10^{-3}
GO:0051798	Positive regulation of hair follicle development	7	1: FST	0.01	9.7×10^{-3}
GO:0048630	Skeletal muscle tissue growth	7	1: CHRNA1	0.01	9.7×10^{-3}
GO:1901072	Glucosamine-containing compound catabolic process	7	1: CH3L1	0.01	9.7×10^{-3}

655

656 **Supplemental Information**

657 **Primary supplement.** PDF. Figures S1-S10 and Table S1, S3-S5.

658 **Table S2.** Excel. Complete list of transcriptome-wide genes for each model in each tissue type as well
659 as their test statistics.

660

661 **Table S6.** Excel. Differentially expressed isoforms as estimated from the IsoformSwitchAnalyzeR
662 implementation of DEXSeq.